

## Synthesis and antibacterial activity of some Pyrazoline derivatives

Y.S. CHOVIATIA<sup>1\*</sup>, S.P. GANDHI<sup>2</sup>, P.L. GORDE<sup>3</sup> and S.B. BAGADE<sup>1</sup>

<sup>1</sup>SVKM's NMIMS, School of Pharmacy and Technology Management, Shirpur - 425405 (India).

<sup>2</sup>A.I.S.S.M.S., College of Pharmacy, Pune, Kennedy Road, Near R.T.O., Pune - 411 001 (India).

<sup>3</sup>Sanjivani College of Pharmaceutical Education and Research, Sahajanandnagar, Kopergaon, Dist. Ahmadnagar (India).

(Received: December 01, 2009; Accepted: January 10, 2010)

### ABSTRACT

Pyrazoline derivatives, being used as potential medicinal agents, a series P<sub>1</sub>-P<sub>5</sub> containing 3,5-diphenylpyrazoline and N-phenyl-3,5-diphenylpyrazoline derivatives were synthesized, structures were confirmed using melting point, IR, NMR and MS and evaluated for their antibacterial activity using disc diffusion method at concentration 2mg/ml. The reference used was amikacin and mostly, all synthesized compounds exhibited a significant antibacterial activity against *Staphylococcus aureus* (MTCC No. 96) as Gram positive bacteria, *Staphylococcus epidermidis* (MTCC No. 435) as Gram positive and *Escherichia coli* (MTCC No. 739) as Gram negative bacteria. It was observed that P<sub>1</sub> and P<sub>2</sub> possess good antibacterial potential against *S. aureus*, P<sub>5</sub> against *S. epidermidis* and P<sub>1</sub> and P<sub>4</sub> against *E. coli*.

**Key words:** Pyrazoline, Disc diffusion method, Amikacin.

### INTRODUCTION

For combating bacterial infection wide variety of anti-bacterial agents has been synthesized<sup>1</sup>.

Pyrazolines are important nitrogen-containing five-member heterocyclic compounds. Several Pyrazoline derivatives possess important pharmacological activities and therefore they are useful materials in drug research. Pyrazolines are used as antitumour<sup>2</sup>, immunosuppressive<sup>3</sup>, antibacterial<sup>4</sup> and antitubercular agents. Some of the pyrazoline derivatives are reported to possess antiinflammatory<sup>5</sup>, anticancer<sup>6</sup>, antidiabetic<sup>7</sup> and antidepressant properties<sup>8</sup>. It also finds applications as dyestuffs, analytical reagents and agrochemicals<sup>9</sup>. Encouraged by its anti-bacterial

activity, it was thought of interest to synthesize a new series of pyrazoline derivatives.

Aldol condensation between acetophenone and substituted benzaldehyde yields chalcone derivatives, a condensation product. These chalcone derivatives were reacted with phenyl hydrazine and hydrazine hydrate to form N-phenyl-3,5-diphenylpyrazoline & 3,5-diphenylpyrazoline derivatives respectively. The characterization of various synthesized compounds was done by TLC, melting point, IR, NMR & MS.

### EXPERIMENTAL

#### Materials

Materials used in synthesis of compounds P<sub>1</sub>-P<sub>5</sub> includes, benzaldehyde, chloro benzaldehyde,

*o*-methoxy benzaldehyde, acetophenone, potassium hydroxide pellets, phenyl hydrazine, hydrazine hydrate, glacial acetic acid, sulphuric acid and ethanol.

### Synthesis

#### General procedure for synthesis of chalcone [P<sub>1</sub> and P<sub>5</sub>]

Trituration was done on adding potassium hydroxide pellets (0.094mol) to the mixture of acetophenone (0.094mol) and benzaldehyde (0.094mol) at room temperature for 1h. The solid product 1,3-diphenyl-2-propen-1-one i.e. chalcone, so obtained was washed with water to remove excess of potassium hydroxide and then dried under UV light.

#### General procedure for synthesis of chalcone derivatives. [P<sub>2</sub>, P<sub>3</sub>, P<sub>4</sub>]

[P<sub>2</sub>] Trituration was done on adding potassium hydroxide pellets (0.072mol) to the mixture of acetophenone (0.072mol) and *o*-methoxy benzaldehyde (0.072mol) at room temperature for

1hr. The solid product 1-phenyl-3-(2-methoxy phenyl)-2-propen-1-one i.e. methoxy substituted chalcone so obtained was washed with water to remove excess of potassium hydroxide and then dried under UV light.

[P<sub>3</sub>, P<sub>4</sub>] Trituration was done on adding potassium hydroxide pellets (0.071mol) to the mixture of acetophenone (0.071mol) and *o*-chloro benzaldehyde (0.071mol) at room temperature for 1hr. The solid product 1-phenyl-3-(2-chloro phenyl)-2-propen-1-one i.e. chloro substituted chalcone so obtained was washed with water to remove excess of potassium hydroxide and then dried under UV light.

#### General procedure for synthesis of Pyrazoline derivatives from Chalcone and its derivatives

[P<sub>1</sub>, P<sub>5</sub>] To 1,3-diphenyl-2-propen-1-one i.e. chalcone (0.008mol) in 20ml of 1,4-dioxane, hydrazine hydrate (0.024mol) and phenyl hydrazine (0.024mol) were added for P<sub>1</sub> and P<sub>5</sub> respectively. To these mixtures 2-3 drops of sulphuric acid were

**Table 1: Experimental data of synthesized Pyrazoline compounds**

Compound	R	X/Y	Molecular formula	m.p. (°C)	% Yield
P <sub>1</sub>	H	X	C <sub>15</sub> H <sub>14</sub> N <sub>2</sub>	44-46	60
P <sub>2</sub>	OCH <sub>3</sub>	X	C <sub>16</sub> H <sub>16</sub> ON <sub>2</sub>	52-54	30
P <sub>3</sub>	Cl	Y	C <sub>21</sub> H <sub>17</sub> N <sub>2</sub> Cl	129	53
P <sub>4</sub>	Cl	X	C <sub>15</sub> H <sub>13</sub> N <sub>2</sub> Cl	50-52	52
P <sub>5</sub>	H	Y	C <sub>21</sub> H <sub>18</sub> N <sub>2</sub>	72-74	45

**Table 2: Microbiological results of Pyrazoline compounds**

Compound	MIC (mg/ml)	% Inhibition		
		<i>S.aureus</i>	<i>E.coli</i>	<i>S.epidermidis</i>
P <sub>1</sub>	2	59	54	50
P <sub>2</sub>	2	62	-	45
P <sub>3</sub>	2	-	48	52
P <sub>4</sub>	2	51	56	52
P <sub>5</sub>	2	51	48	56

(-) Indicates bacteria are resistant to the compounds at concentration 2mg/ml, MIC - minimum inhibitory concentration, i.e., lowest concentration to completely inhibit bacterial growth.



screw capped bottles and sterilized by dry heat at 50°C for 3hrs. Each disc containing full concentration (2mg/ml) were prepared using dimethylformamide (DMSO). The discs of each compounds was placed individually on nutrient agar medium seeded with fresh bacteria respectively using amikacin as the positive control. The nutrient agar plates were incubated at 37°C for 30min. before the discs were applied aseptically. The treated plates were incubated at 37°C for 48h. Minimum Inhibitory Concentrations (MIC) were noted and compared with positive control amikacin, the results of antibacterial studies are given:

The investigation of antibacterial screening data revealed that all the tested compounds showed moderate to good bacterial inhibition action.

## CONCLUSION

We have synthesized a series of 3,5-diphenylpyrazoline and N-phenyl-3,5-diphenylpyrazoline derivatives. The synthesized compound P<sub>1</sub> and P<sub>2</sub> shows significant antibacterial activity against *S. aureus*, P<sub>1</sub> and P<sub>4</sub> against *E. coli* and P<sub>5</sub> against *S. epidermidis*. Also P<sub>3</sub> compound shows adequate activity against *E. coli* and *S. epidermidis*. Hence, it is concluded that there is ample scope for further study in developing these as good lead compounds.

## ACKNOWLEDGEMENTS

The author C.Y.S. is thankful to Pawar S.S. for her assistance in the research work and to his colleagues Sutaria B.S., Morjaria R.M., Wagh P.R., Deore A.S. and Shah J.J. for their help.

## REFERENCES

1. Ozdemir A., Zitouni G. T., Kaplancikli Z. A., Revial G., Guven K., *Eur. J. Med Chem.*, **42**: 403-409 (2007).
2. Taylor E.C., Patel H., Kumar H., *Tetrahedron*, **48**: 8089-8100 (1992).
3. Lombardino J.G., Otterness I.G., *J. Med. Chem.*, **20**: 830-834 (1977).
4. Holla B.S., Akberali P.M., Shivananda M.K., *Il Farmaco*, **55**: 256-263 (2000).
5. Bansal E., Srivatsava V.K., Kumar A., *Eur. J. Med. Chem.*, **36**: 81-92 (2001).
6. Manna F., Chimenti F., Fioravanti R., Bolasco A., Secci D., Chimenti P., Ferlini C., Scambia G., *Bioorg. Med. Chem. Lett.*, **15**: 4632-4635 (2005).
7. Ahn J.H., Kim H.M., Jung S.H., Kang S.K., Kim K.R., Rhee S.D., Yang S.D., Cheon H.G., Kim S.S., *Bioorg. Med. Chem. Lett.*, **14**: 4461-4465 (2004).
8. Prasad Y.R., Rao A.L., Prasoona L., Murali K., Kumar P.R., *Bioorg. Med. Chem. Lett.*, **15**: 5030-5034 (2005).
9. Mulder R., Wellinga K., Van Daalen J.J., *Naturwissenschaften*, **62**: 531-532 (1975).
10. Cruickshank R., Duguid J.P., Marion B.P., Swain R.H.A., Twelfth ed., *Medicinal Microbiology*, vol. II, Churchill Livingstone, London, 196-202 (1975).
11. Collins A.H. (Ed.), *Microbiological Methods*, second ed. Butterworth, London (1976).